VisEn Medical, a provider in fluorescence in-vivo imaging from research through medicine, has launched a new VivoTag 680 XL fluorescent dye for labeling biomolecules in a broad range of in vitro and in vivo imaging applications.
VisEn’s new near-infrared label VivoTag 680 XL adds an additional imaging label to its current portfolio of VivoTag fluorescent dyes which are used to label specific biomolecules and ligands of interest in a wide variety of in vivo and in vitro imaging applications.
The new VivoTag 680 XL is designed for efficient labeling of target molecules under standard research conditions, and is optimized for in vivo and cell-based imaging performance, including superior brightness, biocompatibility and stability in biologic environments.
The new VivoTag 680 XL will be suitable for labeling of non-quenching, targeted or physiologic agents, and imaging in related applications. The fluorescence wavelength is matched for biological imaging applications on a range of in vitro and in vivo fluorescence systems, including the VisEn FMT 2500 LX quantitative tomography system, which also has expanded wavelength capabilities to enable simultaneous imaging of up to four agents and different biomarkers of interest in vivo.
VisEn’s fluorescence imaging agents and labels are designed to provide the industry’s range of biologically-specific imaging readouts. VisEn offers over 30 different fluorescence molecular agents for imaging key disease-associated biologic targets, processes and pathways.
VisEn also offers specialized lines of agent labeling platforms, including its VivoTag fluorescence labeling dyes and its NanoSpark nanoparticles, for customized fluorescence agent labeling. They are all designed and optimized specifically for biocompatibility, brightness, stability and performance in biological imaging applications including cell-based and in vivo imaging applications.
All VisEn agents and labels are designed for in vivo biomarker quantification using VisEn’s Fluorescence Molecular Tomography (FMT) imaging systems, or for general use along with other non-quantitative fluorescence in vivo imaging systems.
VisEn agents are also designed to enable complementary in vitro biomarker readouts in cells and tissues using standard fluorescence microscopy and cellular-based imaging systems. With a focus on translational research and results, all of VisEn’s technologies are designed to generate translational data linking pre-clinical research into clinical medicine.